Biocommercialization: Providing Enabling Policy Environments

Similar documents
Ministry of Industry. Indonesia s 4 th Industrial Revolution. Making Indonesia 4.0. Benchmarking Implementasi Industri 4.0 A.T.

The 21 st APEC Small and Medium Enterprises Ministerial Meeting Joint Ministerial Statement. Nanjing, China September 5, 2014

The future of Research Universities in Asia: Reading the water well AND creating exciting new streams

Re-engineering Collaborative Mechanisms and Knowledge Networks to Accelerate Innovation for Alzheimer s

TRANSFORMATION INTO A KNOWLEDGE-BASED ECONOMY: THE MALAYSIAN EXPERIENCE

Elsevier LibraryConnect Seminar 9 July 2012, InterContinnental Hotel, Makati Lourdes J Cruz, PhD NAST, NRCP & UPMSI

SME Internationalization and Measurement (Presentation)

Are Asia-Pacific Advances in Higher Education & Research Sustainable?

Science, Technology & Innovation Policy: A Global Perspective. Dr Lauren Palmer Australian Academy of Technological Sciences & Engineering (ATSE)

Second APEC Ministers' Conference on Regional Science & Technology Cooperation (Seoul, Korea, Nov 13-14, 1996) JOINT COMMUNIQUÉ

Smart Cities. Smart Cities Indicator Survey Highlights

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships

The Third APEC Ministers Conference on Regional Science and Technology Cooperation. Mexico City, October 21-23, 1998 DRAFT JOINT COMMUNIQUE

TIA Overview (Offerings & Funding Application Process) TIA Eastern Cape Roadshow August 18, 2016

Resilient Innovation for Economic Transformation

2010 IRI Annual Meeting R&D in Transition

TECHNOLOGY VISION 2017 IN 60 SECONDS

Higher School of Economics, Vienna

Chapter 11 Cooperation, Promotion and Enhancement of Trade Relations

EVCA Strategic Priorities

Mid-Atlantic - Eurasia Business Council (MAEBC/MARBC)

American Chamber of Commerce in Taipei

DIRECTION OF SCIENCE, TECHNOLOGY AND INNOVATION POLICY IN THAILAND

Science, technology and engineering for innovation and capacity-building in education and research UNCTAD Wednesday, 28 November 2007

OECD s Innovation Strategy: Key Findings and Policy Messages

Local Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background

CDP-EIF ITAtech Equity Platform

Draft Plan of Action Chair's Text Status 3 May 2008

Choosing the Right Partner for Global Expansion. Oded Shenkar & Lou Longo

The Internationalization of R&D in India: Opportunities and Challenges. Rajeev Anantaram National Interest Project March 2009

WFEO STANDING COMMITTEE ON ENGINEERING FOR INNOVATIVE TECHNOLOGY (WFEO-CEIT) STRATEGIC PLAN ( )

- The experience and relevance of EU SMEs support in Asia-

Venture Capital Search Highlights

Technology transfer and development: implications of four case studies Session 2

Knowledge Sharing for Advancing EGOV Research, Policy and Practice

Business Models Summary 12/12/2017 1

Technology Leadership Course Descriptions

Good Things Increasing

Traditional & Alternative Business Models for SME Financing in Asia

Innovation Economy. Creating the. Dr. G. Wayne Clough President, Georgia Institute of Technology

DBS GROUP HOLDINGS LTD. 15 th Annual General Meeting & Extraordinary General Meeting. 28 April 2014

Vietnam Navigating the future of IT services sector

Higher Education for Science, Technology and Innovation. Accelerating Africa s Aspirations. Communique. Kigali, Rwanda.

DEVELOPMENT OF SCIENCE, TECNOLOGY, AND INNOVATION IN UKRAINE Oleg Khymenko

Seoul Initiative on the 4 th Industrial Revolution

WIPO-WASME Program on Practical Intellectual Property Rights Issues for Entrepreneurs, Economists, Bankers, Lawyers and Accountants

GLOBAL PRIVATE EQUITY Report Charts

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

15890/14 MVG/cb 1 DG G 3 C

Science, Technology & Innovation Policy Review - the Asian experience. Yu Wing Yin University of Bielefeld

Towards a Prosperous Pakistan: A Strategy for Rapid Industrial Growth

Unleashing Social Entrepreneurship: New Partnerships for a Better World

The Policy Content and Process in an SDG Context: Objectives, Instruments, Capabilities and Stages

They all say it is about the economy. It is more than ratio s, percentages, and growth; it is about the Lives of people

Africa. Prof. Kevin Urama, Executive Director, ATPS Contact Presented at UNESCO Meeting Dakar Senegal

UNESCO Programme. (United Nations Educational, Scientific and Cultural Organization)

Summary of the International Symposium on Strategies for Regional and International Collaboration in Science and Technology

Testimony to European Parliament

The value of innovative pharmaceuticals and the potential for Vietnam. Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016

WORLD LIBRARY AND INFORMATION CONGRESS: 72ND IFLA GENERAL CONFERENCE AND COUNCIL August 2006, Seoul, Korea

International Conference on Research Infrastructures 2014

2010/3 Science and technology for development. The Economic and Social Council,

Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective

UN Countries in the Flyway Partner Ramsar

The Strategy of Promoting Born - Global and High- Growth SMEs

Digital Transformation Delivering Business Outcomes

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

I N D O N E S I A N O C E A N P O L I C Y National Aspirations, Regional Contribution and Global Engagement

LSIF Convenor s Summary Report to CTI

Finnish STI Policy

9 Vaccine SMEs' Needs

Amaze AGM 2017 Non Executive Director Positions

Selected Women s Organizations in Latin America and Asia-Pacific Countries

STATE ADVANCED MANUFACTURING POLICIES AND PROGRAMS. As at February 2018

Learning Lessons Abroad on Funding Research and Innovation. 29 April 2016

Cultivating Entrepreneurial Spirit in Asia

International Cooperation in Horizon 2020

Digital Transformation Delivering Business Outcomes

ABIS 16 th Annual Colloquium Sustainable Development Goals and Data Science. Jikyeong Kang, PhD. President, CEO, and Dean.

COUNTRY: Questionnaire. Contact person: Name: Position: Address:

Science, Research and Information Technology

CAPACITIES. 7FRDP Specific Programme ECTRI INPUT. 14 June REPORT ECTRI number

NEWS RELEASE. Life sciences companies tout their expertise in India

Technology and Competitiveness in Vietnam

COUNCIL OF THE EUROPEAN UNION. Brussels, 9 December 2008 (16.12) (OR. fr) 16767/08 RECH 410 COMPET 550

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

New and Emerging Issues Interface to Science Policy

Bridging the Technology Gap

Research and Innovation Strategy and Action Plan UPDATE Advancing knowledge and transforming lives through education and research

Digital Transformation Delivering Business Outcomes

National Innovation System of Mongolia

Sponsored by WIPO, JPO, and IPOPHL Manila, 29 February 2016

Enabling investment: general factors

Intellectual Property

His Excellency Ambassador Ibrahim Yousif Abdullah Fahkroo, Chief of Protocol

High Level Seminar on the Creative Economy and Copyright as Pathways to Sustainable Development. UN-ESCAP/ WIPO, Bangkok December 6, 2017

The Association s high-level visit to Hong Kong in April 2018

Opportunities and Challenges for Open Innovation

Tel: Mobile:

Innovation Management & Technology Transfer Innovation Management & Technology Transfer

Transcription:

Biocommercialization: Providing Enabling Policy Environments rd Asian Biotechnology Conference Manila, The Philippines November, 00 Gurinder Shahi, MD, PhD, MPH Chairman and CEO, BioEnterprise Asia; Director, Email: gurinder.shahi@gmail.com, 00. All rights of reproduction and reuse reserved

Some Global Trends and Opportunities in BioBusiness Bio-investment around the world - in bio-related infrastructure, R&D and training Non-traditional sources of innovation - rise of China and India; Asia-Pacific, now increasingly Latin America, Eastern Europe/CIS and Mid-East/Africa Growing arbitrage opportunity - cost differentials in R&D / manufacturing / services; time-to-market considerations Responding to major global challenges as well as equity concerns growing need for bioenergy / biofeedstocks; those having the biggest problems (poverty / infectious disease / food shortages / environmental / ecological disasters) typically have least resources and access to knowledge/technology Can we build a truly global biotechnology industry? - competition or cooperation? opportunity to build coopetitive environment by facilitating linkages, technology partnering and transfer between and within regions/bioclusters Financing innovation and value creation - opportunity to build new business models to facilitate development, public health, promote public-private partnership, address trans-border concerns Bottomline: Time for enlightened self-interest, 00. All rights of reproduction and reuse reserved

BioBusiness Innovation Challenges Environment Heavy investment in the life sciences Growing scientific base Expanding portfolio of intellectual property Hurdles/Challenges Limited translation of academic research and technology development into commercial application Lack of strategic and business management expertise in life sciences Lack of smart money funding for concept development, technology validation and business case validation Opportunities and Needs Identifying and nurturing development of high potential know-how and technologies Providing commercial acumen and marketplace orientation Critical business and entrepreneurship development support Dedicated seed financial support for promising enterprises Establishing sustainable life science/biotech start-up companies, 00. All rights of reproduction and reuse reserved

Some Considerations: Asia and BioBusiness Asia is a late entrant in the BioBusiness revolution: USA late 70s/early 0s Canada early 0s Europe mid 0s Australia late 0s/early 000s Asia - 00/00 Latin America -? 007/ Starting late has its benefits: learn from mistakes of those who went before (shorter learning curves) scientific/knowledge/technology base more mature and better validated opportunity to partner and license pre-existing technologies to jumpstart innovation, 00. All rights of reproduction and reuse reserved

Some Summit Innovation and Value Creation Opportunities Healthcare/Biomedical Mainstreaming traditional medicines From generic proprietary formulations Nutraceuticals, cosmeceuticals Diagnostics infectious/tropical disease Medical informatics and Health-IT Wellness and disease management Contract research and contract services (including clinical trials, contract mfg, etc) Agri-Vet and Food Organic farming Plantation of high demand nutraceuticals, cosmeceuticals, biomaterials Transgenics BioPharming Diagnostics infectious disease Vaccines and therapeutics Environmental/Industrial Biomaterials and bioplastics Sustainable energy Biofeedstocks Pollution control and environmental clean-up technologies Waste management New industrial enzymes/applications Other Key Areas Bioinformatics/computational biology Outsource information management and services Molecular modeling and simulations Systems biology Life science education and human resource development, 00. All rights of reproduction and reuse reserved

Understanding the BioBusiness Innovation and Commercialization Pipeline responding to market realities Increasing Value Proposition Decreasing Execution Risk Focus on management and business development Focus on science and technology Concept Technology Validation Productization Commercial Product and Service Devt Business Case Validation Market Entry and Rapid Growth Research (new insights and understanding) Development (translation of insights to practical reality) Application (commercial and social application), 00. All rights of reproduction and reuse reserved

BioPartnering: Capturing the Value Proposition Work for win-win Researchers Encourage public-private partnership Industry Academic Entrepreneurs Regulatory Bodies Finance Development Agencies Bet on people Professional Services Legal /IPR, Media, Recruitment etc Make smart investments Source: Shahi, BioBusiness in Asia (Pearson Prentice Hall, 00)

Our Analysis: Successful BioBusiness Environments Critical Success Factors (given good infrastructure, facilities, policies, etc): Smart People Smart Ideas Smart Money (immaterial if public or private sector driven: Silicon Valley model driven by private money; European model driven by public money) Smart Alliances and Partnerships (throughout the world) Key Differentiator - The quality of money: Smart Money versus No Brainer Money. Note: Access to capital alone not sufficient!, 00. All rights of reproduction and reuse reserved

Some Public Policy Considerations: Creating Enabling Environments Infrastructure Development General Physical Scientific/Technical Regulatory and Cultural Environment Government Policies Human Resources Scientists/Technologists Managers of Science/Technology Financing Public Private, 00. All rights of reproduction and reuse reserved

Survey Results: Perceived Strengths and Capabilities in Biotech Innovation of Selected Asia-Pacific Economies Japan Australia Israel Singapore Korea Chinese Taipei New Zealand Hong Kong China India Malaysia Thailand Indonesia Philippines Infrastructure Dev t Physical Infrastructure 0 Scientific Infrastructure 7 0 Regulatory & Cultural Env t 7 0 Human Resource Dev t 0 Finance & Resource Mobilization Public Funding 7 0 Private Funding 7 Overall Ranking [Note: Survey was conducted by Asia-Pacific IMBN Secretariat from August-December. 0 leading experts from around the region were invited to share their perception of scientific development in the region. The results are based on inputs from of these experts. Australia (), Chinese Taipei (), Japan (), Korea (), Phlippines (), Singapore ()] Gov t Policy, 00. All rights of reproduction and reuse reserved 7 0

Recommendations: Making Things Happen Engage the interest and support of the best and the brightest in the region and internationally Invest in bioinnovation and bioentrepreneurship development International agencies and national governments can provide the framework, academic collaboration can support innovation, but private players (and, where appropriate, NGOs) are best placed to drive sustainable implementation and value creation facilitate B-to-B cooperation (across regions) where market forces apply incentivize alignment of economically rational behavior and social good through incentives where market forces do not traditionally apply Cross-training: ensuring that scientists understand what it takes to bring innovation from the bench to the marketplace ensuring that policy-makers understand the issues and concerns of scientists, entrepreneurs and technology enterprises building managers of science with a strong foundation in science and good understanding of marketplace realities and the translational process Making populations bio-literate: understanding ethical and social issues and considerations adult education in life sciences and biotechnology - as important as computer literacy? revamping our school curricula starting modern life science education early in schools, 00. All rights of reproduction and reuse reserved

Conclusions. We are fast approaching critical mass in BioBusiness value creation as innovative technologies mature and come to fruition.. BioBusiness success will come to those players who create a confluence of enlightened investment (smart money) in bioinnovation (smart ideas) and bioentrepreneurship (smart people) and who are well plugged in to working synergistically with key players around the world (smart alliances and partnerships).. There is clear opportunity and need to invest in building up the requisite skills, knowledge and competence to drive innovation and capture the value that the BioBusiness revolution will bring.. Asia is well placed to be a major player and partner in building global value in the BioBusiness arena., 00. All rights of reproduction and reuse reserved

About The Inter-disciplinary think-tank dedicated to: - Thought Leadership - Research and Policy Analysis - Professional Education and Training - Focus on training Managers of Science through our innovative Marshall Executive Program in BioBusiness: - Strategic Management of Innovation and New Product Development - Governance and Management of World-Class Bio Enterprises - Financial and Investment Planning in International BioBusiness - Market and Business Development in BioBusiness - Best Practice Management and BioEthics - Project and Program Management and Advisory/Consulting Services, 00. All rights of reproduction and reuse reserved